ARV-771_LCMS_24246_MedChemExpress
一种肺炎支原体IgG化学发光免疫测定试剂盒及其制备方法[发明专利]
![一种肺炎支原体IgG化学发光免疫测定试剂盒及其制备方法[发明专利]](https://img.taocdn.com/s3/m/a1eeb0c6af45b307e971976b.png)
专利名称：一种肺炎支原体IgG化学发光免疫测定试剂盒及其制备方法
专利类型：发明专利
发明人：周湧,徐向红,夏福臻,钱纯亘,刘星
申请号：CN201610503653.0
申请日：20160630
公开号：CN106053440A
公开日：
20161026
专利内容由知识产权出版社提供
摘要：本发明公开了一种肺炎支原体IgG化学发光免疫测定试剂盒，所述试剂盒包括：肺炎支原体抗原包被的磁微粒、吖啶酯标记的鼠抗人IgG抗体、肺炎支原体IgG定标品、预激发液、激发液。
另外本发明还公开了一种肺炎支原体IgG化学发光免疫测定试剂盒的制备方法。
本发明所述试剂盒与现有试剂盒相比操作简便，灵敏度高，检测范围广等优点。
申请人：深圳市亚辉龙生物科技股份有限公司
地址：518057 广东省深圳市南山区南山街道兴海路荔山工业区5栋1-4层
国籍：CN
更多信息请下载全文后查看。
碧云天细胞自噬染色检测试剂盒(MDC法)说明书
细胞自噬染色检测试剂盒(MDC 法)产品简介：碧云天生产的细胞自噬染色检测试剂盒(MDC 法)，即Autophagy Staining Assay Kit with MDC ，是一种使用丹酰尸胺，也称单丹磺酰尸胺、丹酰尸胺或丹酰戊二胺(monodansylcadaverine, MDC)作为荧光探针快速便捷地检测细胞自噬的试剂盒。
自噬(autophagy)是一种在进化上高度保守的通过溶酶体吞噬并降解部分自身组分的细胞内分解代谢途径。
自噬与多种生理功能有关，在饥饿等环境条件下，细胞通过自噬降解多余或异常的细胞内组分，为细胞的生存提供能量及原材料，促进生物体的生长发育、细胞分化及对环境变化产生应答。
自噬异常与多种病理过程如肿瘤、神经退行性疾病、代谢疾病、病原体感染等都有密切关系。
由于细胞自噬在生理和病理过程中都有重要作用，自噬已经成为细胞生物学领域的一个研究热点。
MDC 是细胞自噬检测最常用的荧光探针之一。
MDC 可以通过离子捕获(ion trapping)和与膜脂的特异性结合，从而特异性标记自噬体(autophagosome)，也称autophagic vacuole ，因而常用于细胞自噬的检测。
MDC 是一种嗜酸性荧光探针，很多酸性膜性结构也会被MDC 染色，因此MDC 染色时正常的细胞也会有一定的染色背景。
本产品的染色原理决定了本产品只能用于培养的细胞或者组织的细胞自噬荧光染色检测，不能用于冻存的或固定的细胞、组织或者组织切片的染色检测。
使用本产品染色后可以通过荧光显微镜拍照观察，也可以通过荧光酶标仪或流式细胞仪进行荧光检测。
荧光显微镜观察时可以使用紫外区激发光激发，发出绿色荧光。
荧光酶标仪或流式细胞仪推荐的激发波长为335nm (330-360nm 均可)，发射波长为512nm (510-540nm 均可)。
本产品用于细胞自噬染色的效果参考图1。
图1. 细胞自噬染色检测试剂盒(MDC 法)的染色效果图。
T0070907_LCMS_04465_MedChemExpress
=====================================================================Acq. Operator : Li Shan(LCMS-02) Seq. Line : 50Acq. Instrument : HY-LCMS-02 Location : P1-C-01Injection Date : 5/15/2015 12:20:58 PM Inj : 1Inj Volume : 3.000 µlAcq. Method : D:\AGLIENT 1260\DATA\20150515\20150515 2015-05-15 08-47-06\100-1000MS+3MIN-1.5_(0.02%FA).MLast changed : 5/15/2015 8:47:06 AM by Li Shan(LCMS-02)Analysis Method : D:\AGLIENT 1260\METHOD\BL30-90A,210NM(RP-HPLC).MLast changed : 5/15/2015 3:12:48 PM by Li Shan(LCMS-02)(modified after loading)M ethod Info : HPLC Catalog No : HY-13202 Batch#04465 A-RP-132Additional Info : Peak(s) manually integratedmin0.51 1.52 2.53mAU20040060080010001200DAD1 C, Sig=254,4 Ref=off (D:\AGLIENT...0\DATA\20150515\20150515 2015-05-15 08-47-06\CPK2015-515-04465.D)1.362 1.462 1.8372.110=====================================================================Area Percent Report=====================================================================Sorted By : SignalMultiplier : 1.0000Dilution : 1.0000Do not use Multiplier & Dilution Factor with ISTDsSignal 1: DAD1 C, Sig=254,4 Ref=offPeak RetTime Type Width Area Height Area# [min] [min] [mAU*s] [mAU] %----|-------|----|-------|----------|----------|--------|1 1.362 MM 0.0528 1.80688 5.70622e-1 0.03642 1.462 MM 0.0554 4955.89258 1490.00452 99.88903 1.837 MM 0.0677 2.64214 6.50008e-1 0.05334 2.110 MM 0.0641 1.05738 2.74959e-1 0.0213Totals : 4961.39899 1491.50011=====================================================================*** End of Report ***===========================================================Acq. Operator : Li Shan(LCMS-02) Seq. Line : 50Acq. Instrument : HY-LCMS-02 Location : P1-C-01Injection Date : 5/15/2015 12:20:58 PM Inj : 1Inj Volume : 3.000 µlAcq. Method : D:\AGLIENT 1260\DATA\20150515\20150515 2015-05-15 08-47-06\100-1000MS+3MIN-1.5_(0.02%FA).MLast changed : 5/15/2015 8:47:06 AM by Li Shan(LCMS-02)Analysis Method : D:\AGLIENT 1260\METHOD\BL30-90A,210NM(RP-HPLC).MLast changed : 5/15/2015 3:14:15 PM by Li Shan(LCMS-02)(modified after loading)M ethod Info : HPLC Catalog No : HY-13202 Batch#04465 A-RP-132Additional Info : Peak(s) manually integratedmin 0.51 1.52 2.530100000200000300000400000500000600000700000800000MSD1 TIC, MS File (D:\AGLIENT 1260\DATA\20150515\20150515 2015-05-15 08-47-06\CPK2015-515-04465.D) ES-API, Pos, Sc1.466MS Signal: MSD1 TIC, MS File, ES-API, Pos, Scan, Frag: 50 Spectra averaged over upper half of peaks. Noise Cutoff: 1000 counts. Reportable Ion Abundance: > 10%.Retention Mol. WeightTime (MS) MS Area or Ion1.466 4473754 280.00 I279.00 I278.00 Im/z 100200300400500600020406080100*MSD1 SPC, time=1.434:1.507 of D:\AGLIENT 1260\DATA\20150515\20150515 2015-05-15 08-47-06\CPK2015-515-04465.D ES-API Max: 432781279.0 278.0 *** End of Report ***。
Gelucire-14-44-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
一种用于从血清中检测叶酸含量的解离剂及检测方法[发明专利]
![一种用于从血清中检测叶酸含量的解离剂及检测方法[发明专利]](https://img.taocdn.com/s3/m/9f25780c172ded630a1cb6cf.png)
专利名称：一种用于从血清中检测叶酸含量的解离剂及检测方法
专利类型：发明专利
发明人：陶然
申请号：CN201911416335.0
申请日：20191231
公开号：CN111024962A
公开日：
20200417
专利内容由知识产权出版社提供
摘要：本发明涉及一种用于从血清中检测叶酸含量的解离剂及检测方法，包括蛋白变性剂、蛋白水解酶、表面活性剂和基础液，其中各组分的用量为：每100ml解离剂中含有蛋白变性剂3～8g，蛋白水解酶1000～3000U，表面活性剂0.2～0.8ml，余量为基础液。
与现有技术相比，本发明具有方法简单，灵敏度高、检测结果准确等优点。
申请人：上海复星长征医学科学有限公司
地址：200444 上海市宝山区城银路830号
国籍：CN
代理机构：上海科盛知识产权代理有限公司
代理人：蒋亮珠
更多信息请下载全文后查看。
Febuxostat_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Febuxostat(TEI 6720;TMX 67 ) is selective xanthine oxidase inhibitor with Ki of 0.6 nM.IC50 value: 0.6 nM (Ki) [1]Target: xanthine oxidasein vitro: Febuxostat displays potent mixed–type inhibition of the activity of purified bovine milk xanthine oxidase, with Ki and Ki' values of 0.6 nM and 3.1 nM respectively, indicating inhibition of both the oxidized and reduced forms of xanthine oxidase [1].in vivo: Febuxostat (5–6 mg/kg/day) combined with fructose significantly lowers blood pressure, UA, triglycerides, and insulin in rats compared with fructose alone. Febuxostat (5–6 mg/kg/day) combined with fructose also reduces glomerular pressure, renal vasoconstriction, and afferent arteriolar area in rats compared with fructose alone [2]. Febuxostat prevents hyperuricemia in 5/6nephrectomy (5/6 Nx)+oxonic acid (OA)+Febuxostat(Fx) rats and ameliorates proteinuria, preserves renal function and prevents glomerular hypertension in both 5/6 nephrectomy (5/6 Nx)+vehicle (V)+Febuxostat(Fx) and 5/6 nephrectomy (5/6 Nx)+oxonic acid (OA)+Febuxostat(Fx) groups [3]. Febuxostat (5 mg/kg/d by gavage for 8 days) treatment after transverse aortic constriction (TAC)attenuates the TAC–induced left ventricular (LV) hypertrophy and dysfunction. Febuxostat blunts the TAC–induced increases innitrotyrosine (indicating reduced myocardial oxidative stress), p–Erk(Thr202/Tyr204), and p–mTOR(Ser2488), with no effect on total Erk or total mTOR [4].References:[1]. Takano Y, et al. Selectivity of febuxostat, a novel non–purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci, 2005, 76(16), 1835–1847.[2]. Sánchez–Lozada LG, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose–induced metabolic syndrome. Am J Physiol Renal Physiol, 2008, 294(4), F710–F718.[3]. Sánchez–Lozada LG, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol, 2008, 108(4), p69–p78.[4]. Xu X, et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload–induced left ventricular hypertrophy and dysfunction in mice. Card Fail, 2008, 14(9), 746–753.Product Name:Febuxostat Cat. No.:HY-14268CAS No.:144060-53-7Molecular Formula:C 16H 16N 2O 3S Molecular Weight:316.37Target:Xanthine Oxidase Pathway:Metabolic Enzyme/Protease Solubility:10 mM in DMSOCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
LCMS检测西他沙星原料中基因毒性杂质的含量
LC-MS检测西他沙星原料中基因毒性杂质的含量石莹1宋雪洁3李浩冬2路显锋2*1药物研究院分析所，扬子江药业集团，泰州2253212药物制剂新技术国家重点实验室，扬子江药业集团，泰州2253213质量管理部，扬子江药业集团，泰州225321摘要建立了LC-MS 法测定西他沙星中基因毒性杂质对甲苯磺酸甲酯和对甲苯磺酸乙酯含量的方法。
方法:采用Agilent Poroshell 120 EC-C18色谱柱；流动相为纯水（0.1%甲酸）:甲醇（V/V）=60:40；稀释剂为乙腈（0.1%甲酸）:纯水（V/V）=50:10；柱温为40℃；进样体积为5µl；流速为0.4ml/min；采用正离子模式进行扫描。
对甲苯磺酸甲酯测定浓度在0.76ng/ml~15.27ng/ml范围内，线性关系良好；对甲苯磺酸乙酯测定浓度在0.75ng/ml~15.01ng/ml范围内，线性关系良好。
对甲苯磺酸甲酯的定量限为0.0038ng；对甲苯磺酸乙酯的定量限为0.0038ng。
杂质回收率在限度浓度80%、100%和160%三个浓度水平均在90~110%之间，该方法准确度良好。
该方法适用于西他沙星原料中对甲苯磺酸甲酯和对甲苯磺酸乙酯的检测。
西他沙星(sitafloxacin)是日本第一制药有限公司继左氧氟沙星后开发出的一种强力广谱新氟喹诺酮类抗菌剂，该药对革兰氏阳性球菌，革兰氏阴性菌以及厌氧菌的抗菌活性是左氧氟沙星的4～32倍，同时对肺炎球菌DNA 促旋酶和拓扑同功酶有双重抑制作用。
临床表现有极广的抗菌谱，特别是对呼吸道的病菌有极强的抗菌活性。
因西他沙星的一个起始物料为对甲苯磺酸盐，在后续反应中对甲苯磺酸若有残留，可能会与溶剂甲醇、乙醇反应生成具有基因毒性的杂质—对甲苯磺酸甲酯和对甲苯磺酸乙酯，故采用LC-MS法对产品中的对甲苯磺酸甲酯/乙酯进行控制。
1、实验部分1.1仪器与试药Agilent 1200液相色谱仪(美国安捷伦公司)；Agilent 6460三重串联四极杆质谱仪(美国安捷伦公司)；XP205型电子天平(瑞士梅特勒托利多公司)。
高效液相色谱法测定染发剂中的α-萘酚
高效液相色谱法测定染发剂中的α-萘酚
殷勤
【期刊名称】《中国公共卫生》
【年(卷),期】1997(13)3
【摘要】高效液相色谱法测定染发剂中的α－萘酚辽宁省卫生防疫站（沈阳１１
０００５）殷勤α－萘酚作为中间体，主要应用在染料、油脂、农药的合成与生产中。
在化妆品行业，可作为着色剂用于染发剂中。
α－萘酚具有致癌、致畸、致敏、致突变的潜在毒性，对眼、皮肤有刺激性，大量...
【总页数】1页(P179-179)
【关键词】染发剂;α;萘酚;毒性;高效液相色谱
【作者】殷勤
【作者单位】辽宁省卫生防疫站
【正文语种】中文
【中图分类】R168;TQ658.34
【相关文献】
1.高效液相色谱-串联质谱法同时测定染发剂中的1-萘酚和2-萘酚 [J], 康明芹;李爱军;牟峻;张代辉;胡婷婷;杨帆
2.高效液相色谱法测定染发剂中α-萘酚 [J], 虞柯洁;周耀明;童红武;刘少民
3.反相高效液相色谱法测定尿中α-萘酚、β-萘酚、对硝基酚和间硝基酚 [J], 黎俊宏;李贵荣;唐宏兵;徐晓怡;欧阳运富;王永生;杨红梅
4.高效液相色谱法测定硫酸锌电解液中的α-亚硝基-β-萘酚、β-萘酚 [J], 万有岳;李琼莉
5.高效液相色谱法测定盐酸特芘萘酚乳膏中的盐酸特芘萘酚 [J], 梁振芬;鞠福龙;齐峰;邢宇;王佳祥
因版权原因，仅展示原文概要，查看原文内容请购买。